The Future of JAK Inhibitors Figure 1

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.

Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.

Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.

Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.

Sling Therapeutics closes a $123 million Series C to advance linsitinib, while Circle Pharma raises an oversubscribed $92.5 million Series E to move CID-165, into clinical development for ER-positive breast cancer.

CGT commercial trajectories are set years before approval — and every development decision is an access decision.